IG: State Dept Should Produce 12 FRUS Volumes Per Year
The Department of State must begin producing new volumes of the Foreign Relations of the United States (FRUS) series at a rate of a dozen volumes per year if it is going to fulfill its statutory mandate to document the history of U.S. foreign policy not later than 30 years after the fact, the State Department Inspector General said in a new report (pdf).
“The [State Department Historian’s Office] is behind schedule in meeting the statutory FRUS deadline: HO historians only now are compiling the contents of the volumes covering the foreign policy of the Carter administration (1977-1981),” the Inspector General report said. “To achieve compliance with the 30-year deadline, HO will need to accelerate the rate of publication to approximately 12 volumes per year.”
The IG audit found that after a controversial period of management turmoil in 2007 and 2008 culminating in a 2009 IG inspection report (pdf), conditions in the Historian’s Office had stabilized, with “improved morale, reduced factionalism, and [a] strengthened spirit of civility” as well as “greater openness and a more participatory style of management.” But more recently, as the pace of internal reform has slowed, “morale has begun to decline.”
See “Report of Inspection: The Bureau of Public Affairs,” U.S. Department of State Office of Inspector General, February 2010, at pp. 34-38.
With wildfire risk increasing and the potential for destruction along with it continues to grow nationwide, the Federation of American Scientists (FAS) today joins with other organizations to launch a new coalition, Partners in Wildfire Prevention.
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.